Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19759
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSiva, Shankar-
dc.contributor.authorChesson, Brent-
dc.contributor.authorBressel, Mathias-
dc.contributor.authorPryor, David-
dc.contributor.authorHiggs, Braden-
dc.contributor.authorReynolds, Hayley M-
dc.contributor.authorHardcastle, Nicholas-
dc.contributor.authorMontgomery, Rebecca-
dc.contributor.authorVanneste, Ben-
dc.contributor.authorKhoo, Vincent-
dc.contributor.authorRuben, Jeremy-
dc.contributor.authorLau, Eddie-
dc.contributor.authorHofman, Michael S-
dc.contributor.authorDe Abreu Lourenco, Richard-
dc.contributor.authorSridharan, Swetha-
dc.contributor.authorBrook, Nicholas R-
dc.contributor.authorMartin, Jarad-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorKron, Tomas-
dc.contributor.authorForoudi, Farshad-
dc.date2018-10-23-
dc.date.accessioned2018-11-04T23:50:37Z-
dc.date.available2018-11-04T23:50:37Z-
dc.date.issued2018-10-23-
dc.identifier.citationBMC Cancer 2018; 18(1): 1030en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19759-
dc.description.abstractStereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell cancer (RCC) in patients that are medically inoperable or at high-risk of post-surgical dialysis. The objective of the FASTRACK II clinical trial is to investigate the efficacy of SABR for primary RCC. FASTRACK II is a single arm, multi-institutional phase II study. Seventy patients will be recruited over 3 years and followed for a total of 5 years. Eligible patients must have a biopsy confirmed diagnosis of primary RCC with a single lesion within a kidney, have ECOG performance ≤2 and be medically inoperable, high risk or decline surgery. Radiotherapy treatment planning is undertaken using four dimensional CT scanning to incorporate the impact of respiratory motion. Treatment must be delivered using a conformal or intensity modulated technique including IMRT, VMAT, Cyberknife or Tomotherapy. The trial includes two alternate fractionation schedules based on tumour size: for tumours ≤4 cm in maximum diameter a single fraction of 26Gy is delivered; and for tumours > 4 cm in maximum diameter 42Gy in three fractions is delivered. The primary outcome of the study is to estimate the efficacy of SABR for primary RCC. Secondary objectives include estimating tolerability, characterising overall survival and cancer specific survival, estimating the distant failure rate, describing toxicity and renal function changes after SABR, and assessment of cost-effectiveness of SABR compared with current therapies. The present study design allows for multicentre prospective validation of the efficacy of SABR for primary RCC that has been observed from prior single institutional and retrospective series. The study also allows assessment of treatment related toxicity, overall survival, cancer specific survival, freedom from distant failure and renal function post therapy. Clinicaltrials.gov NCT02613819 , registered Nov 25th 2015.en_US
dc.language.isoeng-
dc.subjectAblationen_US
dc.subjectAdrenalen_US
dc.subjectKidneyen_US
dc.subjectMetastasesen_US
dc.subjectNephrectomyen_US
dc.subjectRCCen_US
dc.subjectSABRen_US
dc.subjectSBRTen_US
dc.titleTROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBMC Canceren_US
dc.identifier.affiliationPrincess Alexandra Hospital, Brisbane, QLD, Australiaen_US
dc.identifier.affiliationCalvary Mater Newcastle, Newcastle, NSW, Australiaen_US
dc.identifier.affiliationCentre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, Australiaen_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationAlfred Health and Monash University, 55 Commercial Rd, Melbourne, 3004, Australiaen_US
dc.identifier.affiliationUniversity of Adelaide, Royal Adelaide Hospital, Adelaide, South Australia, Australiaen_US
dc.identifier.affiliationPeter MacCallum Cancer Centre, 305 Grattan Street Melbourne, Melbourne, 3000, Australiaen_US
dc.identifier.affiliationUniversity of Melbourne, Royal Parade, Parkville, 8006, Australiaen_US
dc.identifier.affiliationRadiation Oncologyen_US
dc.identifier.affiliationTrans Tasman Radiation Oncology Group (TROG), Waratah, Australiaen_US
dc.identifier.affiliationMAASTRO Clinic, Maastricht, The Netherlandsen_US
dc.identifier.affiliationRoyal Marsden Hospital, London, UKen_US
dc.identifier.doi10.1186/s12885-018-4916-2en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-2840-0658en_US
dc.identifier.orcid0000-0001-8387-0965en_US
dc.identifier.orcid0000-0001-8553-5618en_US
dc.identifier.pubmedid30352550-
dc.type.austinJournal Article-
local.name.researcherForoudi, Farshad
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptRadiology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptRadiation Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.